Skip to Content

18 Results Found

  • Review
  • Open Access
10 Citations
3,655 Views
12 Pages

27 September 2024

Idiosyncratic drug-induced liver injury (iDILI) by flucloxacillin presents as both cholestatic and hepatocellular injury. Its mechanistic steps are explored in the present analysis as limited data exist on the cascade of events leading to iDILI in pa...

(This article belongs to the Special Issue Inflammation, Immunity, and Tissue Regeneration: New Treatments and Future Directions)
  • Article
  • Open Access
23 Citations
5,101 Views
12 Pages

24 September 2021

The LiverTox database compiles cases of idiosyncratic drug-induced liver injury (iDILI) with the promised aims to help identify hepatotoxicants and provide evidence-based information on iDILI. Weaknesses of this approach include case selection merely...

(This article belongs to the Section Machine Learning and Artificial Intelligence in Diagnostics)
  • Review
  • Open Access
44 Citations
6,249 Views
16 Pages

Progress in understanding the mechanisms of the idiosyncratic drug induced liver injury (iDILI) was highlighted in a scientometric investigation on the knowledge mapping of iDILI throughout the world, but uncertainty remained on metabolic risk factor...

(This article belongs to the Special Issue Toxic Liver Injury: Molecular, Mechanistic, and Medical Challenges)
  • Review
  • Open Access
11 Citations
4,559 Views
17 Pages

The human leucocyte antigen (HLA) allele variability was studied in cohorts of patients with idiosyncratic drug-induced liver injury (iDILI). Some reports showed an association between HLA genetics and iDILI, proposing HLA alleles as a potential risk...

  • Review
  • Open Access
78 Citations
8,235 Views
39 Pages

29 September 2020

Background: A large number of idiosyncratic drug induced liver injury (iDILI) and herb induced liver injury(HILI) cases of variable quality has been published but some are a matter of concern if the cases were not evaluated for causality using a robu...

(This article belongs to the Special Issue Research Topics in Medicines and How Our Board Members Are Engaged in Them)
  • Review
  • Open Access
11 Citations
5,303 Views
21 Pages

14 February 2025

Conventionally, drug-induced liver injury (DILI) exists in two types: idiosyncratic and intrinsic. Both types are classified as non-immune disorders, thereby ignoring that some iDILI cases may have an immune or autoimmune background that requires a d...

  • Article
  • Open Access
17 Citations
5,818 Views
22 Pages

Idiosyncratic Drug-Induced Liver Injury and Amoxicillin–Clavulanate: Spotlight on Gut Microbiota, Fecal Metabolome and Bile Acid Profile in Patients

  • Sara Román-Sagüillo,
  • Raisa Quiñones Castro,
  • María Juárez-Fernández,
  • Polina Soluyanova and ,
  • Camilla Stephens,
  • Mercedes Robles-Díaz,
  • Francisco Jorquera Plaza,
  • Javier González-Gallego,
  • Susana Martínez-Flórez and
  • Sonia Sánchez-Campos
  • + 8 authors+ 3 authors

Several hepatic disorders are influenced by gut microbiota, but its role in idiosyncratic drug-induced liver injury (iDILI), whose main causative agent is amoxicillin–clavulanate, remains unknown. This pioneering study aims to unravel particula...

(This article belongs to the Special Issue Molecular Mechanisms of Human Liver Diseases 2.0)
  • Review
  • Open Access
12 Citations
8,555 Views
37 Pages

19 August 2023

Drugs are prescribed worldwide to treat diseases but with the risk of idiosyncratic drug-induced liver injury (iDILI). The most important difficulty is how best to establish causality. Based on strong evidence and principles of artificial intelligenc...

  • Review
  • Open Access
16 Citations
17,273 Views
29 Pages

Drug-Induced Liver Injury—Pharmacological Spectrum Among Children

  • Bianca Raluca Maris,
  • Alina Grama and
  • Tudor Lucian Pop

25 February 2025

Drug-induced liver injury (DILI) is one of the main causes of acute liver failure in children. Its incidence is probably underestimated, as specific diagnostic tools are currently lacking. Over 1000 known drugs cause DILI, and the list is expanding....

(This article belongs to the Section Molecular Immunology)
  • Review
  • Open Access
102 Citations
17,232 Views
26 Pages

Idiosyncratic Drug-Induced Liver Injury: Mechanistic and Clinical Challenges

  • Alison Jee,
  • Samantha Christine Sernoskie and
  • Jack Uetrecht

Idiosyncratic drug-induced liver injury (IDILI) remains a significant problem for patients and drug development. The idiosyncratic nature of IDILI makes mechanistic studies difficult, and little is known of its pathogenesis for certain. Circumstantia...

(This article belongs to the Special Issue Toxic Liver Injury: Molecular, Mechanistic, and Medical Challenges)
  • Review
  • Open Access
24 Citations
5,948 Views
22 Pages

Clinical and mechanistic considerations in idiosyncratic drug-induced liver injury (iDILI) remain challenging topics when they are derived from mere case narratives or iDILI cases without valid diagnosis. To overcome these issues, attempts should be...

(This article belongs to the Special Issue Molecular Toxicity of Drugs in Human and Animal Organs)
  • Review
  • Open Access
250 Citations
26,162 Views
25 Pages

Drug-induced liver injury (DILI) can broadly be divided into predictable and dose dependent such as acetaminophen (APAP) and unpredictable or idiosyncratic DILI (IDILI). Liver injury from drug hepatotoxicity (whether idiosyncratic or predictable) res...

(This article belongs to the Special Issue Molecular Research on Drug Induced Liver Injury)
  • Article
  • Open Access
7 Citations
5,549 Views
17 Pages

Hepatotoxicity or drug-induced liver injury (DILI) is a major safety issue in drug development as a primary reason for drug failure in clinical trials and the main cause for post-marketing regulatory measures like drug withdrawal. Idiosyncratic DILI...

(This article belongs to the Section Health Outcomes of Antioxidants and Oxidative Stress)
  • Review
  • Open Access
11 Citations
6,209 Views
27 Pages

25 May 2023

Drug-induced liver injury (DILI) is a major contributor to high attrition rates among candidate and market drugs and a key regulatory, industry, and global health concern. While acute and dose-dependent DILI, namely, intrinsic DILI, is predictable an...

(This article belongs to the Special Issue Liver Constituent Cells: Their Niche, Close Intercellular Relationship and Crosstalk with the Extracellular Environment—Current and Future Perspectives)
  • Review
  • Open Access
4 Citations
2,414 Views
27 Pages

30 September 2025

Drug-induced autoimmune hepatitis (DIAIH) is a rare and complex disorder caused by drugs that are commonly metabolized by hepatic microsomal cytochrome P450 (CYP) pathways. Whereas DIAIH presents generally with a single clinical flare, in rare cases...

(This article belongs to the Section Molecular Endocrinology and Metabolism)
  • Review
  • Open Access
20 Citations
3,446 Views
18 Pages

Drug-induced autoimmune hepatitis (DIAIH) is a relatively new subtype of idiosyncratic drug-induced liver injury (iDILI), but the features of DIAIH have been variably described due to the inhomogeneity of assessed study cohorts. The aim of this analy...

(This article belongs to the Special Issue Diagnosis and Management of Liver Diseases—2nd Edition)
  • Review
  • Open Access
31 Citations
8,351 Views
25 Pages

Molecular and Clinical Links between Drug-Induced Cholestasis and Familial Intrahepatic Cholestasis

  • Giovanni Vitale,
  • Alessandro Mattiaccio,
  • Amalia Conti,
  • Sonia Berardi and ,
  • Vittoria Vero,
  • Laura Turco,
  • Marco Seri and
  • Maria Cristina Morelli
  • + 3 authors+ 0 author

Idiosyncratic Drug-Induced Liver Injury (iDILI) represents an actual health challenge, accounting for more than 40% of hepatitis cases in adults over 50 years and more than 50% of acute fulminant hepatic failure cases. In addition, approximately 30%...

(This article belongs to the Special Issue Toxic Liver Injury: Molecular, Mechanistic, and Medical Challenges 2.0)
  • Article
  • Open Access
18 Citations
5,709 Views
9 Pages

Liraglutide-Induced Hepatotoxicity

  • Yaakov Maor,
  • David Ergaz,
  • Stephen D. H. Malnick,
  • Ehud Melzer and
  • Manuela G. Neuman

A 52-year-old woman with a BMI of 31.2 kg/m2 was treated with the glucagon-like peptide 1 (GLP-1) agonist liraglutide as part of her weight-reduction program. Following this, she developed an idiosyncratic drug-related liver injury (IDILI). Advances...

(This article belongs to the Special Issue Experimental and Translational Research on Liver Disease)